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CASE REPORT Open Access
Polysubstance-induced relapse of
schizoaffective disorder refractory to
high-dose antipsychotic medications: a
case report
Murray G. Tucker1, Sebastian Kekulawala1, Michelle Kent1, Sam Mostafa2 and Richard Harvey1,3*
Abstract
Background: The high prevalence of comorbid illicit drug use in persons with chronic psychotic illness represents
a strong determinant of psychotic relapse and rehospitalization. Epidemiological studies indicate changing patterns
of illicit drug use in Australia, which are concerning because of increased use of crystal methamphetamine, also
known as “ice.” An important complication of habitual use of crystal methamphetamine is the development of a
dose-dependent acute psychotic reaction. We report a case of an acute psychotic relapse in response to polydrug
use most notable for multiple recent binges of crystal methamphetamine. Unlike previously described case reports,
our patient’s acute psychosis was refractory to ultra-high doses of multiple antipsychotic medications. This
presented safety challenges due to the risk of serious side effects with high-dose antipsychotic medications.
Case presentation: A 30-year-old white man with a past history of schizoaffective disorder was brought to our
emergency department by the police in a state of extreme agitation, combativeness, and paranoia after use of cannabis
and crystal methamphetamine. Despite existing compliance with zuclopenthixol decanoate depot medication, he
required multiple emergency injections of zuclopenthixol acetate, and regular high-dose droperidol, chlorpromazine,
and lorazepam. However, he remained severely agitated and psychotic with continuous threats of harm to others. A
test of antipsychotic drug metabolism by cytochrome P450 enzymes did not reveal a pharmacogenetic cause for the
poor therapeutic efficacy of antipsychotic medications. His psychosis did not appear to be modified by psychoactive
medications but was instead self-limited to the presence of endogenous methamphetamine within his system. He fully
recovered 96 to 120 hours post-presentation and was discharged home with out-patient clinic follow-up.
Conclusions: The current case highlights the challenging nature of a severe psychotic relapse precipitated by illicit
substances that is resistant to medical management. High doses of multiple antipsychotic medications may be
required to manage dangerous behaviors associated with these acute psychotic relapses. These patients require
close monitoring for adverse effects with adjustment of dosing to ensure the optimal balance of risk versus benefit
while the patient is acutely psychotic. The results are of relevance for the management of psychiatric emergencies
in emergency departments and acute mental health settings.
Keywords: Methamphetamine, Substance-induced psychosis, Psychiatric emergencies, Rapid sedation,
Medication safety, Pharmacogenetic testing
Abbreviations: ADHD, Attention deficit hyperactivity disorder; DASA, Dynamic Appraisal of Situational Aggression;
eGFR, Estimated glomerular filtration rate; IM, Intramuscular; IV, Intravenous; PO, Per oral; QT interval, The interval in
milliseconds between the Q wave and T wave on an electrocardiogram
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Background
Illicit drug use is a significant problem among persons
with major mental illness. The 2010 Australian National
Survey of Psychotic Disorders reported psychoactive
substance abuse in 63 % of men and 41 % of women
with psychosis, compared with 12 % of men and 6 % of
women in the general population [1]. This high comor-
bidity represents one of the biggest barriers to effective
management of schizophrenia and related disorders
since substance use can reduce compliance with medica-
tions, exacerbate psychosis, precipitate a major relapse
of illness requiring hospitalization, and increase treat-
ment resistance over the lifetime of the illness [2, 3]. It
has been hypothesized that the high comorbidity of illicit
drug use and chronic psychotic disorders may reflect an
inherent neurobiological vulnerability to developing a
substance abuse disorder, a strategy to alleviate symp-
toms of the primary mental illness or the adverse effects
of medications, or that patterns of use may simply re-
flect the local availability of illicit substances [4].
The illicit drugs of choice for persons with major
psychotic disorders are most frequently cannabis
followed by stimulants such as cocaine, amphetamine,
and methamphetamine. Approximately 11 % of persons
with schizophrenia abuse cannabis and stimulants con-
currently [2]. One psychostimulant of particular interest
is crystalline methamphetamine, also known as “ice,”
which is both highly addictive and growing in popularity.
Ice use reportedly more than doubled from 22 % to 50 %
among illicit amphetamine users in Australia between
2010 and 2013 [5]. The frequency of daily or weekly ice
use also doubled from 12.4 % to 25 % over the same
period [5]. Correspondingly there have been increased
public concerns about the drug’s detrimental impact on
mental and physical health, social functioning, crime
rates, and public safety since intoxicated users have a
propensity towards hostility and interpersonal violence
[6]. Escalation in the use of ice has thus resulted in a
predictable rise in methamphetamine-related presenta-
tions to Australian emergency departments [6, 7].
A relatively common illness associated with habitual
or binge use of methamphetamine is a transient psychotic
reaction. For individuals without a history of primary
psychotic illness, this psychotic reaction is referred to as
methamphetamine-induced acute psychosis. Compara-
tively, for individuals with a pre-existing primary psychotic
disorder, this psychotic reaction is referred to as an acute
psychotic relapse precipitated by methamphetamine
abuse. The clinical features of methamphetamine-induced
acute psychosis commonly include hallucinatory experi-
ences and persecutory delusions accompanied by hostile
behavior [8]. Bizarre delusions, formal thought disorder,
or negative symptoms are less common [8–10]. Conse-
quently, methamphetamine-induced acute psychosis can
appear remarkably similar to acute paranoid schizophrenia
[11]. The time course of methamphetamine-induced acute
psychosis is normally brief, lasting hours to a few days,
with patients usually making a full recovery with abstin-
ence [12]. It has been reported that patients with
methamphetamine-induced acute psychosis normally re-
spond well to antipsychotic medications [13]. However,
there have been very few reports of severely unwell pa-
tients with either methamphetamine-induced acute psych-
osis or methamphetamine-precipitated psychotic relapse
who respond poorly to antipsychotic medications and the
safety issues that arise in this scenario.
Case presentation
A 30-year-old white man was brought to our emergency
department by the police under the Mental Health Act
in an aggressive and combative state threatening suicide
and homicide. His presentation was precipitated by daily
cannabis use and multiple binges of ice over the prior
month. His past psychiatric history included childhood
attention deficit hyperactivity disorder (ADHD) and
schizoaffective disorder which was managed on a Com-
munity Treatment Order with fortnightly 300 mg zuclo-
penthixol decanoate intramuscular injections. His past
medical history was remarkable for polysubstance abuse.
From 15 years of age he regularly used tobacco, alcohol,
and cannabis, and sporadically used heroin, hallucinogens,
ecstasy, and amphetamines. In terms of family history, his
father had ADHD and one historical episode of manic
psychotic illness requiring treatment with medication and
electroconvulsive therapy. His male sibling was deceased
from suicide after protracted illness with major depression
and binge eating disorder. Our patient had a long history
of transient living and difficulty sustaining regular employ-
ment in bricklaying. At the time of presentation, he was
living in a shared residence and using ice most days in the
context of interpersonal conflict, unemployment, financial
stressors, and housing stressors.
On his arrival at our emergency department, six-point
mechanical restraint was required for his safety and for
the safety of the staff and co-patients. An initial physical
examination revealed Glasgow Coma Score of 14 (Eyes
4, Voice 4, Motor 6), tachycardic pulse 110 beats/minute,
blood pressure 125/63 mmHg, fingertip oxygen saturation
95 % on room air, and tympanic temperature 36.1 °C. A
subsequent physical examination revealed that his pupils
were equal and reactive to light, heart sounds were dual
with nil added sounds or murmurs, chest auscultation was
normal bilaterally, abdomen was soft and non-tender, and
upper and lower limbs were neurologically intact based on
gross examination. An electrocardiogram could not be
recorded due to his combative behavior. He claimed that
he had been stabbed in the torso by his flatmate despite
no evidence of any external injuries. A full blood
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examination, C-reactive protein test, random blood glu-
cose test, liver function tests, thyroid function tests, and
ethanol level were unremarkable. Renal function tests re-
vealed mild hypokalemia, his potassium (K+) was 3.2, and
mild acute kidney injury, his creatinine was 126 and esti-
mated glomerular filtration rate (eGFR) was 66, secondary
to poor oral intake. His dehydration was treated with 1 L
of 0.9 % normal saline solution administered intravenously
due to his refusal to take food and fluids orally.
Rapid sedation was commenced with ziprasidone, lor-
azepam, droperidol, and zuclopenthixol acetate (Table 1).
Benztropine was administered for prophylaxis against
extrapyramidal side effects of the antipsychotic medica-
tions. The level of sedation attained was unsatisfactory
as he remained severely agitated and combative inter-
spersed with only brief periods of drowsiness. He could
not follow direction or adhere to boundaries established
by staff. All attempts at de-escalation and distraction
were met with aggression.
After psychiatric review in our emergency department
he was transferred to a closed seclusion room on the
psychiatric ward. He scored maximally on the Dynamic
Appraisal of Situational Aggression (DASA) scale [14].
Droperidol 25 mg and lorazepam 2 mg were
administered intramuscularly four times a day under
physical restraint. His vital signs were measured every 4
hours; they remained within normal limits and no extra-
pyramidal side effects were observed.
A psychiatric review was re-attempted 27 hours into
closed seclusion. However, this review was impossible be-
cause he remained extremely agitated and uncooperative.
Interactions with our patient during seclusion checks
revealed an absence of perceptual disturbances, thought
disorder, or delusions of reference. He was no longer com-
plaining of being stabbed in the torso, but continued to
express paranoid thought content. A urine drug screen
was positive for methamphetamine, benzodiazepines, and
tetrahydrocannabinol. A recheck of his renal function was
not performed because he was now consuming regular
food and fluids and his urine output was normal.
After 72 hours of emergency psychiatric treatment,
high-dose antipsychotic medications administered intra-
muscularly remained ineffective. He was becoming
slightly more cooperative with nursing staff requests
despite his continued aggression. Intramuscular adminis-
tration of droperidol was ceased and oral administration
of chlorpromazine syrup 300 mg four times a day and
lorazepam 2 mg four times a day was commenced
(Table 2). A second prophylactic dose of benztropine
was also administered at this time. An urgent electrocar-
diogram revealed that his QT-corrected interval was
normal (432 ms).
His DASA score remained maximal despite his accept-
ance of oral medications. His behavior was marked by
severe aggression, hostility, threats to kill, punching and
kicking of the seclusion door, periods of loud abuse, im-
pulsivity, and unpredictability. This behavior continued
despite treatment which consisted of high-dose anti-
psychotic medications and lorazepam for 3 days. An ur-
gent application was made to the Mental Health
Tribunal for electroconvulsive therapy to treat his psych-
otic relapse. This application was subsequently with-
drawn when there was a sudden improvement in his
mental state at 96 hours of treatment. His aggression
settled to a DASA score of 4 out of 7 with only low-level
irritability and no further threats of suicide or homicide.
A repeat urine drug screen revealed a trace amount of
methamphetamine.
He was engaged and cooperative for the first time at
review 120-hours post-presentation. He reported that he
felt threatened by people who he alleged were trying to
stab him. However, he was able to acknowledge that his
paranoia was possibly caused by a relapse of his mental
illness. He denied any psychotic or affective symptoms,
or any thoughts, intent, or plans to harm himself or
others. There were no signs of major mental illness that
required ongoing in-patient treatment, and he was dis-
charged home on a Community Treatment Order with
Table 1 Medications administered to the patient in our
emergency department and selected behavioral observations
Time Medication name, dose,
and route
Behavioral observations
1720 Approximate time of
presentation to our
emergency department
Extremely aggressive,
threatening, and offensive
behavior and language
1726 Ziprasidone 20 mg IM,
lorazepam 2 mg IM
1730 Lorazepam 2 mg IM
1740 Zuclopenthixol acetate
150 mg IM, benztropine
2 mg IM
1805 Lorazepam 2 mg IV Vital signs and IV access
obtained, blood sampled
1830 Droperidol 10 mg IM Verbally abusive, threatening,
aggressive
2230 Ziprasidone 20 mg IM
2300 Lorazepam 2 mg IV
0100 Sedated and quiet
0400 Droperidol 10 mg IM,
Lorazepam 2 mg IV
Yelling, abusive, shaking bed,
threatening staff
0600 Sedated but intermittent
abuse and threats
1120 Ziprasidone 20 mg IM
1300 Droperidol 25 mg IM Acute arousal, combative
during transport to
psychiatric ward
IM intramuscular, IV intravenous
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continued zuclopenthixol decanoate depot medication.
After discharge, he engaged regularly with our mental
health service to receive his depot. He continued to use
cannabis daily and crystal methamphetamine once or
twice per week. His mental state remained stable during
out-patient psychiatric reviews with occasional vague
auditory hallucinations. He had no further admissions to
acute psychiatric units during a period of 18 months
post-discharge.
Discussion
The current case highlights the difficulty of managing
severe agitation in acutely psychotic patients whose
symptoms are refractory to antipsychotic medications.
The patient experienced a psychotic relapse of his schi-
zoaffective disorder which was precipitated by polydrug
use, most notable for daily cannabis use and multiple
binges of crystal methamphetamine. A strong relation-
ship between heavy methamphetamine use and the de-
velopment of acute psychotic illness is well documented
[11]. In those with chronic psychotic illness, comorbid
illicit amphetamine use can exacerbate active psychosis
or cause a relapse of psychotic illness that was previously
in remission [8]. This observation has been verified in
studies which experimentally administered a small
dose of a stimulant drug to patients with schizophrenia
and elicited a dramatic increase in positive psychotic
symptoms and occasionally a reduction in negative
symptoms [15]. Exacerbation of psychotic illness by
stimulants is not necessarily prevented by existing
compliance with antipsychotic medications [3, 15],
which was observed in our patient since he was com-
pliant with fortnightly 300 mg zuclopenthixol decanoate
injections prior to his relapse.
Currently there are no clear guidelines for the man-
agement of acute psychosis precipitated by illicit drugs
[16]. Antipsychotic medications, with or without benzo-
diazepines, are normally effective in standard doses and
are widely used [17]. A prospective randomized study
[13] administered 2 to 4 mg of lorazepam or 2.5 to 5
mg of droperidol intravenously to 166 severely agi-
tated persons presenting to an emergency department
with methamphetamine-induced acute psychosis or
methamphetamine-precipitated relapse of a psychotic
disorder. The patients’ behavior generally settled to
cooperative, somnolent, or easily roused within 30
Table 2 Medications administered every 24 hours since presentation to our emergency department
Time since presentation to
emergency department
Total medication doses
over 24-hour period
Daily chlorpromazine equivalence Daily diazepam equivalence
0–24 hours Lorazepam IV/IM 10 mg 50 mg
Ziprasidone IM 60 mg 300 mg
Droperidol IM 45 mg 900 mg
Zuclopenthixol acetate IM 150 mg 300 mg
Benztropine IM 2 mg
24–48 hours Lorazepam IM 6 mg 30 mg
Droperidol IM 100 mg 2000 mg
Zuclopenthixol acetate IM 150 mg 300 mg
48–72 hours Lorazepam IM 8 mg 40 mg
Lorazepam PO 2 mg 10 mg
Droperidol IM 50 mg 1000 mg
Zuclopenthixol acetate IM 100 mg 200 mg
Chlorpromazine PO 300 mg 300 mg
72–96 hours Lorazepam PO 16 mg 80 mg
Chlorpromazine PO 1350 mg 1350 mg
Zuclopenthixol acetate IM 100 mg 200 mg
Benztropine PO 2 mg
96–120 hours Lorazepam PO 10 mg 50 mg
Chlorpromazine PO 750 mg 750 mg
Zuclopenthixol decanoate IM 300 mg 450 mga
Benztropine PO 2 mg
Daily chlorpromazine and diazepam equivalence are provided for comparative purposes [31]. IM intramuscular, IV intravenous, PO oral. aZuclopenthixol decanoate
depot of 300 mg/fortnightly is equivalent to 450 mg of chlorpromazine daily over the fortnight
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minutes of administration of either medication. In
contrast, our patient was administered standard doses
of lorazepam, ziprasidone, zuclopenthixol acetate, and
droperidol within the first hour, yet he remained dan-
gerously hostile and combative (see Table 1). Other
prospective randomized studies have reported that
either regular olanzapine and haloperidol [18], quetia-
pine and haloperidol [19], or aripiprazole and risperi-
done [20] produce clinically significant reductions in
psychotic symptomatology in cases of amphetamine-
induced psychosis. Therefore, the current case is remark-
able for severe psychotic agitation that was refractory to
ultra-high doses of multiple antipsychotic medications
and benzodiazepines (see Fig. 1 for cumulative chlorpro-
mazine and diazepam equivalents). The medications did
not seem to alter the clinical course of his relapse. Rather,
his relapse appeared to be self-limited to the clearance of
the endogenous methamphetamine.
To maximize patient safety, physical health checks
occurred at 4-hourly intervals to monitor his vital signs,
mental state, and medication adverse effects. His hostil-
ity made these physical health assessments particularly
difficult. Large and repeated doses of benzodiazepines
may cause hypotension and respiratory depression; how-
ever, this was not observed as his vital signs remained
within normal limits. Droperidol is a high potency anti-
psychotic medication which can cause extrapyramidal
side effects of akathisia and acute dystonic reactions (for
example, torticollis, oculogyric crisis). These side effects
were prevented by administering multiple prophylactic
doses of benztropine. Antipsychotic medications and
methamphetamine may also prolong the QT interval
which increases the risk of life-threatening arrhythmias.
A baseline electrocardiogram could not be recorded due
to combative behavior. However, an electrocardiogram
was later recorded when he became more cooperative
which showed that his QT interval was normal. Given
the refractory nature of his psychosis to medical man-
agement and the high risk of adverse effects of high
doses of antipsychotic medications, we considered elec-
troconvulsive therapy; clinicians may opt for electrocon-
vulsive therapy at an earlier stage in similar psychiatric
emergencies. Electroconvulsive therapy alone or in com-
bination with antipsychotic medications is recom-
mended for treatment-resistant psychotic disorders
when a rapid clinical response is urgently required [8].
Preliminary studies also indicated that electroconvulsive
therapy can induce remission of persistent symptoms of
methamphetamine-induced psychosis [21, 22].
We hypothesized that our patient’s poor clinical re-
sponse was from a genetic polymorphism in the drug-
metabolizing activity of cytochrome P450 enzymes.
Enzyme CYP2D6 metabolizes up to 25 % of commonly
prescribed drugs including antipsychotic medications
such as chlorpromazine, haloperidol and zuclopenthixol
[23]. “Ultra-rapid metabolizers” metabolize antipsychotic
medications at a higher rate than the general population
and require more medication for therapeutic effects [23].
After he had recovered he provided informed consent
for a buccal swab of cheek cells for pharmacogenomic
testing. The results of the test were two normal func-
tioning alleles of the CYP2D6 enzyme, which is an “ex-
tensive metabolizer” phenotype (that is, normal in the
general population), thus refuting our hypothesis. Alter-
native mechanisms underlying refractoriness to anti-
psychotic treatment may include drug interactions,
unknown contaminants within clandestine laboratory-
synthesized methamphetamine, and induction or inhib-
ition of CYP450 enzymes. For instance, our patient
smoked cigarettes which induce the production of
Fig. 1 Cumulative chlorpromazine and diazepam equivalents for antipsychotic and benzodiazepine medications respectively that were administered
to the patient
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CYP1A1, CYP1A2, and CYP2E1 enzymes. Induction of
these enzymes can lower the plasma concentrations of
several psychotropics including chlorpromazine and ben-
zodiazepines [24]. Benztropine has also been reported to
exacerbate psychosis in persons with schizophrenia who
were previously well managed on antipsychotic medica-
tions; however, this effect is controversial [25].
Degenerative changes in a patient’s dopaminergic
pathways may also account for a suboptimal effect of
antipsychotic treatment. Chronic amphetamine abuse is
known to cause enduring structural and functional
changes in dopaminergic systems, which reduces the ef-
ficacy of antipsychotic medications [26]. Lieberman and
colleagues [27] also highlighted that 30 to 60 % of pa-
tients with schizophrenia develop increasing resistance
to standard antipsychotic medication over the natural
course of their illness for reasons that are poorly under-
stood but may involve sensitization to dopamine or
degeneration of dopamine neurocircuitry. Genetic poly-
morphisms in dopaminergic receptors and transporters
have also been identified as risk factors for ADHD and
schizophrenia and are thought to contribute to the dys-
functional dopamine signaling underlying these illnesses
[28, 29]. Moreover, this is the major signaling system tar-
geted by antipsychotic drugs. Of interest, our patient’s
father had comorbid ADHD and manic psychotic dis-
order, and our patient’s male sibling had major depres-
sion and binge eating disorder. Taken together, this
suggests a strong genetic contribution of dysfunctional
dopaminergic signaling to account for our patient’s psy-
chiatric illnesses, as well as the refractory nature of his
psychosis to treatment.
By convention, the technically correct diagnosis in this
case was an acute psychotic relapse of our patient’s schi-
zoaffective disorder which was precipitated by polydrug
use. However in many respects his presentation ap-
peared to be classical for methamphetamine-induced
acute psychosis, which is a diagnosis normally reserved
for individuals without an underlying primary psychotic
disorder. That is, he presented in a state of clear con-
sciousness with non-bizarre persecutory delusions that
his flatmate had stabbed him and was trying to kill him.
His affect was congruent with the content of his para-
noid beliefs and there was no evidence of formal thought
disorder. He was severely agitated with persistent anger
and threatening behavior which seemed to stem from
paranoia of others wanting to harm him in combination
with poor insight, impulsivity, and anti-social personality
traits. His psychotic symptoms also closely followed the
timeline of methamphetamine intoxication since a urine
drug screen performed at the time of his recovery revealed
the clearance of methamphetamine from his system. In
contrast, his previous exacerbations of schizoaffective dis-
order were characterized by a different symptomatology
marked by auditory hallucinations, bizarre persecutory de-
lusions (for example, being haunted by spirits), “pressure
of speech,” and flight ideas which lasted for several weeks.
This is an interesting feature of the case and suggests that
it may be possible to distinguish between drug-induced
psychotic states and alternative mechanisms causing a re-
lapse of manic psychotic illness when the patient’s past
psychiatric history is accurately known [8, 30]. However,
more research is required to clarify this issue.
Conclusions
Our patient experienced a particularly severe acute
psychotic relapse which lasted 96 to 120 hours and
was precipitated by daily cannabis and binges of crys-
tal methamphetamine. His acute psychosis was marked
by continuous severe hostility which was unusually
resistant to ultra-high doses of multiple antipsychotic
and benzodiazepine medications. In these treatment-
refractory cases, there is a significant potential for
harm to the patient, staff, and the public. Risks to the
patient include self-harm, suicide, and adverse effects
of medications. Although the adverse effects of psy-
choactive medications are difficult to monitor in unco-
operative patients they can be life threatening and
thus warrant special attention.
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